Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
HANNAH ALISON L. reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Alison L. Hannah received a grant of 24,400 shares of common stock in the form of Restricted Stock Units. These RSUs vest annually over four years from July 8, 2026, with the first vesting on July 8, 2027. Following adjustments, including the cancellation of 5,750 RSUs for no consideration, she holds 35,025 shares of common stock directly.
Rigel Pharmaceuticals announced a leadership change in its top medical role. Alison L. Hannah, M.D. has been appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026. At the same time, she resigned from Rigel’s Board of Directors, where she had served since May 2021.
Dr. Hannah has worked as a consultant to the pharmaceutical and biotechnology industry since 2000, focusing on investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc. Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel effective June 25, 2026.
Rigel Pharmaceuticals director Kamil Ali-Jackson sold 2,500 shares of common stock at $35.00 per share in an open-market transaction. After the sale, she directly holds 10,125 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025 and, according to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than for investment purposes.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey received a fully vested employee stock option tied to a performance goal. The award covers 7,394 shares of common stock at an exercise price of $22.49 per share. The performance metric was confirmed as met on June 17, 2026, triggering vesting, and the option expires on January 29, 2035. This is a compensation-related grant, not an open-market share purchase or sale.
Rigel Pharmaceuticals EVP and Chief Medical Officer Lisa Rojkjaer reported the vesting of previously granted performance-based stock options. On June 17, 2026, performance metrics were determined to be met for options covering 9,375 shares at an exercise price of $14.90 and 7,394 shares at $22.49.
Both option grants became fully vested on June 17, 2026. The 9,375-share grant was originally made on March 27, 2024 and adjusted for a one-for-ten reverse stock split effective June 27, 2024, while the 7,394-share grant was made on January 29, 2025.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a performance-based stock option grant that became fully vested on June 17, 2026. The award covers 31,700 shares of common stock under an employee stock option, with an exercise price of $22.49 per share and an expiration date of January 29, 2035. The filing shows this as a compensation-related acquisition, not an open-market buy or sale, and lists 31,700 derivative shares held following the transaction.
RIGEL PHARMACEUTICALS EVP and Chief Commercial Officer David A. Santos reported a performance-based stock option award covering 7,394 shares of common stock. The option has an exercise price of $22.49 per share and an expiration date of January 29, 2035.
The award was originally granted on January 29, 2025 with a performance-based vesting condition, and it became fully vested on June 17, 2026 when the company determined that the performance metric had been met.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported the acquisition of an employee stock option covering 7,394 shares of common stock. The option was originally granted on January 29, 2025 with an exercise price of $22.49 per share.
The award carried a performance-based vesting condition and was not reportable until that metric was satisfied. On June 17, 2026, the company determined the performance metric had been met, and the option became fully vested, leaving Schorno with 7,394 option shares following the transaction.
Kamil Ali-Jackson reports a sale of 2,500 shares of common stock. The filing shows 2,500 shares were sold on 05/26/2026 for $72,925.00, with Fidelity Brokerage Services LLC listed as the broker. The securities were reported as vested restricted stock with a vesting date of 05/21/2024.
Rigel Pharmaceuticals, Inc. completed a major licensing transaction, making its License Agreement with Arvinas, Inc., Arvinas affiliates and Pfizer Inc. effective for VEPPANU™ (vepdegestrant). The deal grants Rigel exclusive, global rights to develop, manufacture and commercialize VEPPANU and related products worldwide.
Following early termination of the Hart-Scott-Rodino antitrust waiting period and satisfaction of closing conditions, Rigel closed the transaction and paid the licensors a one-time upfront payment of $70.0 million.